ViroGates Publishes Prospectus for Public Offering
Mon Jun 04 2018
ViroGates, a diagnostic solutions pioneer, has released its IPO prospectus, heralding a new phase of growth. The strategic move aims to bolster capital for expansion initiatives.
The IPO plan encompasses invigorating commercial efforts, boosting product development, enhancing clinical documentation, and broadening global patent coverage. By issuing new shares and listing on Nasdaq First North, ViroGates targets DKK 60-75 million, with DKK 53.7 million commitments from cornerstone investors.
The capital influx will energize several key strategies:
- Expanding Commercial Reach (60-70%): A strong sales presence in Europe and strategic partnerships aim to widen the reach of diagnostic solutions.
- Catalyzing Product Development (10-20%): Funds will propel ongoing innovation in diagnostic solutions.
- Elevating Clinical Documentation (5-10%): Additional clinical documentation will enhance credibility and user confidence.
- Global Patent Security (5-10%): Funds will secure global patent coverage for recent suPARnostic® application patent.
ViroGates aspires to achieve positive cash flow by end of 2020 and acquire 40 paying hospital customers, demonstrating a commitment to transformative growth.
In a dynamic medical technology landscape, ViroGates’ IPO propels them toward innovation and impact. The focus now shifts to product innovation and prudent resource use as ViroGates forges ahead, reshaping medical technology through dedication to excellence.
More information to be found in ViroGates´ announcement published on June 4 here;
Read more in the press reviews here (in Danish):
Finans.dk; Medicoselskab vil på børsen
MedWatch; ViroGates går på børsen i København
Berlingske Business.dk; Coloplast-milliardærer bag ny børsnotering